All Stories

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it.

Apr 22, 2025 - 13:58
 0
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it.
Read More

Tags:

Previous Article

Heartland Coca-Cola picks founder's son as new CEO

Next Article

Former Neumora CEO to lead Galapagos spinout

Related Posts

CDMO PharmaLogic takes majority stake in Norway's Agilera to boost global radiopharma footprint

CDMO PharmaLogic takes majority stake in Norway's Agile...

Apr 9, 2025  0

Bristol Myers' cost-savings drive claims another 223 jobs in NJ

Bristol Myers' cost-savings drive claims another 223 jo...

Mar 3, 2025  0

With Eli Lilly flying high, CEO David Ricks collects 10% pay bump to $29.2M

With Eli Lilly flying high, CEO David Ricks collects 10...

Mar 10, 2025  0